Unichem Laboratories Ltd
Unichem Laboratories Q4 FY17 earnings call: Revenue & Margins
Q4 FY17 investor presentation: what the company reported on revenue, margins and projects.
Based on Unichem Laboratories Ltd's Q4 FY17 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the presentation reports, not management guidance.
The short version
Quarter ended March 31, 2017 revenue from operations: INR 18,735 lakhs, up 7% YoY (from INR 17,447 lakhs in Q4 FY16) (Page 38). - Domestic formulations sales: Not explicitly separated here, but domestic operations including formulations increased as part of total. - API revenue (Standalone basis): INR 11,852 lakhs for the quarter, up 18% YoY (Page 38). - Total income for the quarter: INR 34,393 lakhs, up 13% YoY. - EBITDA margin for Q4 FY17 was 9.8% (Page 38). - Earning per share (EPS) Q4 FY17: INR 3.35, up 8% YoY (Page 38). - No explicit forward-looking revenue or volume guidance provided within these pages of the presentation. Quarter ended March 31, 2017 (Q4 FY17) Standalone Financials (INR Lakhs): - EBITDA: ₹3,146 Lakhs, 14% growth YoY - Operating Income (Operating Profit): ₹2,299 Lakhs, 9% growth YoY - Profit After Tax (PAT): ₹2,305 Lakhs, -14% decline YoY - Margins: - EBITDA margin: 9.1% for Q4 FY17, steady compared to 9.1% in Q4 FY16 - Operating margin: 7.3% for Q4 FY17, down from 8.3% in Q4 FY16 - PAT margin: approx.
From Unichem Laboratories Ltd's Q4 FY17 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Quarter ended March 31, 2017 revenue from operations: INR 18,735 lakhs, up 7% YoY (from INR 17,447 lakhs in Q4 FY16) (Page 38).
- Domestic formulations sales: Not explicitly separated here, but domestic operations including formulations increased as part of total.
- API revenue (Standalone basis): INR 11,852 lakhs for the quarter, up 18% YoY (Page 38).
- Total income for the quarter: INR 34,393 lakhs, up 13% YoY.
- EBITDA margin for Q4 FY17 was 9.8% (Page 38).
2 more points management made on revenue & sales performance
Profitability & Margins
See what Unichem Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- SEZ Pithampur: Construction started (page 6).
- Expansion at API facility in Pithampur: Commenced (page 6).
- Acquisition of API facility in Kolhapur, Maharashtra (page 6).
- Commissioned expanded capacities at Goa Formulation plant, significantly increasing capacities (page 6).
- Realignment and further sub-divisionalization of Chronic business with increased focus on Chronic; launched new division on Cardio & Neuro (page 6).
- Construction of R&D Centre at Goa started (2012) and relocation of R&D from Mumbai to Goa as Centre of Excellence, with filings commissioned from new R&D Centre (page 6).
- Baddi II plant commissioned (2007-08).
- Purchase of additional land at Goa (year not specified; page 6).
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Unichem Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Unichem Laboratories Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹575 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Unichem Laboratories Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- FDC Ltd (Q4 FY17)
The year-on-year revenue growth for Q4 FY 2017 was 3.7%. Key concall takeaways from FDC Ltd's Q4 FY17 earnings call — and how it ranks against sector peers.
Frequently Asked Questions
What were Unichem Laboratories Ltd Q4 FY17 results?
Quarter ended March 31, 2017 revenue from operations: INR 18,735 lakhs, up 7% YoY (from INR 17,447 lakhs in Q4 FY16) (Page 38). - Domestic formulations sales: Not explicitly separated here, but domestic operations including formulations increased as part of total. - API revenue (Standalone basis): INR 11,852 lakhs for the quarter, up 18% YoY (Page 38). - Total income for the quarter: INR 34,393 lakhs, up 13% YoY. - EBITDA margin for Q4 FY17 was 9.8% (Page 38). - Earning per share (EPS) Q4 FY17: INR 3.35, up 8% YoY (Page 38). - No explicit forward-looking revenue or volume guidance provided within these pages of the presentation. Quarter ended March 31, 2017 (Q4 FY17) Standalone Financials (INR Lakhs): - EBITDA: ₹3,146 Lakhs, 14% growth YoY - Operating Income (Operating Profit): ₹2,299 Lakhs, 9% growth YoY - Profit After Tax (PAT): ₹2,305 Lakhs, -14% decline YoY - Margins: - EBITDA margin: 9.1% for Q4 FY17, steady compared to 9.1% in Q4 FY16 - Operating margin: 7.3% for Q4 FY17, down from 8.3% in Q4 FY16 - PAT margin: approx.
What is Unichem Laboratories Ltd share price analysis?
Unichem Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 31.4 with a market cap of ₹3,842 Cr. Investors should review the full earnings analysis for detailed insights.
Is Unichem Laboratories Ltd planning capital expenditure?
SEZ Pithampur: Construction started (page 6).
Keep Unichem Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.